Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Cardiovascular and cerebrovascular outcomes in elderly hypertensive patients treated with either ARB or ACEI.

Ma C, Cao J, Lu XC, Guo XH, Gao Y, Liu XF, Fan L.

J Geriatr Cardiol. 2012 Sep;9(3):252-7. doi: 10.3724/SP.J.1263.2011.12031.

2.

Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.

Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Ghadanfar M, Weissbach N, Xiang Z, Armbrecht J, Pfeffer MA.

Nephrol Dial Transplant. 2009 May;24(5):1663-71. doi: 10.1093/ndt/gfn721. Epub 2009 Jan 14.

3.

Renin-angiotensin system antagonists and clinical outcomes in stable coronary artery disease without heart failure.

Sorbets E, Labreuche J, Simon T, Delorme L, Danchin N, Amarenco P, Goto S, Meune C, Eagle KA, Bhatt DL, Steg PG.

Eur Heart J. 2014 Jul;35(26):1760-8. doi: 10.1093/eurheartj/ehu078. Epub 2014 Mar 9.

4.

Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation.

Heinze G, Mitterbauer C, Regele H, Kramar R, Winkelmayer WC, Curhan GC, Oberbauer R.

J Am Soc Nephrol. 2006 Mar;17(3):889-99. Epub 2006 Feb 15.

5.
6.

Are angiotensin-converting enzyme inhibitors and angiotensin receptor blockers especially useful for cardiovascular protection?

Ong HT.

J Am Board Fam Med. 2009 Nov-Dec;22(6):686-97. doi: 10.3122/jabfm.2009.06.090094. Review.

7.

Renin-angiotensin-system modulators and the incidence of atrial fibrillation following hospitalization for coronary artery disease.

Singh JP, Kulik A, Levin R, Ellinor PT, Ruskin J, Avorn J, Choudhry NK.

Europace. 2012 Sep;14(9):1287-93. doi: 10.1093/europace/eus074. Epub 2012 Apr 26.

9.

Effects of angiotensin converting enzyme inhibition or angiotensin receptor blockade in dialysis patients: a nationwide data survey and propensity analysis.

Wu CK, Yang YH, Juang JM, Wang YC, Tsai CT, Lai LP, Hwang JJ, Chiang FT, Chen PC, Lin JL, Lin LY.

Medicine (Baltimore). 2015 Jan;94(3):e424. doi: 10.1097/MD.0000000000000424.

10.

Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro- and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trials.

Maione A, Navaneethan SD, Graziano G, Mitchell R, Johnson D, Mann JF, Gao P, Craig JC, Tognoni G, Perkovic V, Nicolucci A, De Cosmo S, Sasso A, Lamacchia O, Cignarelli M, Manfreda VM, Gentile G, Strippoli GF.

Nephrol Dial Transplant. 2011 Sep;26(9):2827-47. doi: 10.1093/ndt/gfq792. Epub 2011 Mar 3. Review.

11.

Angiotensin-Receptor Blocker, Angiotensin-Converting Enzyme Inhibitor, and Risks of Atrial Fibrillation: A Nationwide Cohort Study.

Hsieh YC, Hung CY, Li CH, Liao YC, Huang JL, Lin CH, Wu TJ.

Medicine (Baltimore). 2016 May;95(20):e3721. doi: 10.1097/MD.0000000000003721.

12.

How does inhibition of the renin-angiotensin system affect the prognosis of advanced gastric cancer patients receiving platinum-based chemotherapy?.

Kim ST, Park KH, Oh SC, Seo JH, Kim JS, Shin SW, Kim YH.

Oncology. 2012;83(6):354-60. doi: 10.1159/000337979. Epub 2012 Oct 8.

PMID:
23052034
13.

Effect of Renin-Angiotensin system inhibition on cardiovascular events in older hypertensive patients with metabolic syndrome.

Zreikat HH, Harpe SE, Slattum PW, Mays DP, Essah PA, Cheang KI.

Metabolism. 2014 Mar;63(3):392-9. doi: 10.1016/j.metabol.2013.11.006. Epub 2013 Nov 16.

14.

Influence of hospitalisation on the use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in elderly hypertensive patients.

Wawruch M, Slezakova V, Murin J, Luha J, Bozik M, Leitmann T, Kuzelova M, Shah R.

Aging Clin Exp Res. 2014 Jun;26(3):307-14. doi: 10.1007/s40520-014-0231-1. Epub 2014 Apr 30.

PMID:
24781831
15.
16.

Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE).

Kasanuki H, Hagiwara N, Hosoda S, Sumiyoshi T, Honda T, Haze K, Nagashima M, Yamaguchi J, Origasa H, Urashima M, Ogawa H; HIJ-CREATE Investigators.

Eur Heart J. 2009 May;30(10):1203-12. doi: 10.1093/eurheartj/ehp101. Epub 2009 Apr 4.

17.

Effects of valsartan, an angiotensin II receptor blocker, on coronary atherosclerosis in patients with acute myocardial infarction who receive an angiotensin-converting enzyme inhibitor.

Yano H, Hibi K, Nozawa N, Ozaki H, Kusama I, Ebina T, Kosuge M, Tsukahara K, Okuda J, Morita S, Umemura S, Kimura K.

Circ J. 2012;76(6):1442-51. Epub 2012 Apr 4.

18.

A comparison between angiotensin converting enzyme inhibitors and angiotensin receptor blockers on end stage renal disease and major adverse cardiovascular events in diabetic patients: a population-based dynamic cohort study in Taiwan.

Wu LS, Chang SH, Chang GJ, Liu JR, Chan YH, Lee HF, Wen MS, Chen WJ, Yeh YH, Kuo CT, See LC.

Cardiovasc Diabetol. 2016 Apr 2;15:56. doi: 10.1186/s12933-016-0365-x.

19.
20.

Angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use and cardiovascular outcomes in patients initiating peritoneal dialysis.

Shen JI, Saxena AB, Montez-Rath ME, Chang TI, Winkelmayer WC.

Nephrol Dial Transplant. 2016 Apr 13. pii: gfw053. [Epub ahead of print]

PMID:
27190342
Items per page

Supplemental Content

Write to the Help Desk